Source: Alex Lavoie
A Closer Look at Twist Bioscience’s Financial Performance
Twist Bioscience Corporation, a recognized force in the biotech industry with a specialization in the biomedical and genetics sector, recently reported its latest financial performance. The NASDAQ-listed company (NASDAQ:TWST) is known for its innovative synthetic DNA-based products and services, which have been instrumental in research and development across a wide range of industries, particularly in healthcare and agriculture.
On November 14, 2025, Twist Bioscience shared its earnings report, which demonstrated its resilience and potential for growth despite the highly competitive Zacks Medical – Biomedical and Genetics industry. The report’s key highlights include the company’s EPS and revenue figures, which both surpassed estimates.
Exceeding Earnings Estimates
Twist Bioscience reported an earnings per share (EPS) of -$0.44, performing better than the forecasted EPS of -$0.50. Although the company registered a loss, this figure still represents an improvement from the prior year’s loss of $0.59 per share.
Notably, this loss of $0.44 per share was marginally higher than the Zacks Consensus Estimate of a $0.40 loss, as pointed out by financial analysis firm, Seeking Alpha. This demonstrates that despite the volatile and challenging market conditions, Twist Bioscience has been able to control its losses and perform better than predicted.
Impressive Revenue Growth
In terms of revenue, Twist Bioscience’s financial performance was just as robust. The company reported revenue of approximately $99 million for the quarter, outpacing the projected revenue of $97.4 million. This figure also surpassed the Zacks Consensus Estimate by 1.69%, marking a substantial increase from the $84.71 million reported in the same quarter the previous year.
Twist Bioscience’s track record of consistently exceeding consensus revenue estimates for the past four quarters is a testament to its robust business model and strategic direction.
Investor Confidence and Financial Health
Despite reporting negative earnings, Twist Bioscience’s price-to-earnings (P/E) ratio of approximately -20.42 does not seem to deter investors. The company’s price-to-sales ratio of about 4.21 indicates that investors are willing to pay $4.21 for every dollar of sales. This is a strong indication of investor confidence in Twist Bioscience’s revenue-generating capabilities and future growth potential.
Twist Bioscience also maintains a healthy balance sheet, with a relatively low level of debt as evidenced by a debt-to-equity ratio of about 0.16. The company’s current ratio of approximately 3.64 suggests a strong liquidity position, with ample short-term assets to cover its short-term liabilities.
Looking Ahead
Despite the challenges faced in the market, Twist Bioscience remains steadfast in its strategic direction and potential growth areas, as outlined in its Q4 2025 earnings call. The company’s impressive performance and its commitment to innovation and research in the biomedical and genetics sector make it a compelling option for investors looking to invest in the growing biotech industry.
In conclusion, Twist Bioscience Corporation’s latest financial report underscores the company’s resilience and potential for future growth. The company’s ability to consistently surpass revenue estimates and maintain a healthy balance sheet, despite the challenges it faces, reflects its strategic direction and robust business model.